Literature DB >> 24726895

Activation of AMPK and inactivation of Akt result in suppression of mTOR-mediated S6K1 and 4E-BP1 pathways leading to neuronal cell death in in vitro models of Parkinson's disease.

Yijiao Xu1, Chunxiao Liu1, Sujuan Chen1, Yangjing Ye1, Min Guo1, Qian Ren1, Lei Liu2, Hai Zhang1, Chong Xu1, Qian Zhou1, Shile Huang2,3, Long Chen1.   

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder characterized by loss of dopaminergic neurons. Dysregulation of mammalian target of rapamycin (mTOR) has been implicated in the pathogenesis of PD. However, the underlying mechanism is incompletely elucidated. Here, we show that PD mimetics (6-hydroxydopamine, N-methyl-4-phenylpyridine or rotenone) suppressed phosphorylation of mTOR, S6K1 and 4E-BP1, reduced cell viability, and activated caspase-3 and PARP in PC12 cells and primary neurons. Overexpression of wild-type mTOR or constitutively active S6K1, or downregulation of 4E-BP1 in PC12 cells partially prevented cell death in response to the PD toxins, revealing that mTOR-mediated S6K1 and 4E-BP1 pathways due to the PD toxins were inhibited, leading to neuronal cell death. Furthermore, we found that the inhibition of mTOR signaling contributing to neuronal cell death was attributed to suppression of Akt and activation of AMPK. This is supported by the findings that ectopic expression of constitutively active Akt or dominant negative AMPKα, or inhibition of AMPKα with compound C partially attenuated inhibition of phosphorylation of mTOR, S6K1 and 4E-BP1, activation of caspase-3, and neuronal cell death triggered by the PD toxins. The results indicate that PD stresses activate AMPK and inactivate Akt, causing neuronal cell death via inhibiting mTOR-mediated S6K1 and 4E-BP1 pathways. Our findings suggest that proper co-manipulation of AMPK/Akt/mTOR signaling may be a potential strategy for prevention and treatment of PD.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AMPK; Akt; Neuronal cells; Parkinson's disease; mTOR

Mesh:

Substances:

Year:  2014        PMID: 24726895      PMCID: PMC4039615          DOI: 10.1016/j.cellsig.2014.04.009

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  50 in total

1.  Cell cycle withdrawal promotes myogenic induction of Akt, a positive modulator of myocyte survival.

Authors:  Y Fujio; K Guo; T Mano; Y Mitsuuchi; J R Testa; K Walsh
Journal:  Mol Cell Biol       Date:  1999-07       Impact factor: 4.272

Review 2.  Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease.

Authors:  D Blum; S Torch; N Lambeng; M Nissou; A L Benabid; R Sadoul; J M Verna
Journal:  Prog Neurobiol       Date:  2001-10       Impact factor: 11.685

3.  Regulation of neuronal survival by the serine-threonine protein kinase Akt.

Authors:  H Dudek; S R Datta; T F Franke; M J Birnbaum; R Yao; G M Cooper; R A Segal; D R Kaplan; M E Greenberg
Journal:  Science       Date:  1997-01-31       Impact factor: 47.728

Review 4.  AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy.

Authors:  D Grahame Hardie
Journal:  Nat Rev Mol Cell Biol       Date:  2007-10       Impact factor: 94.444

Review 5.  Parkinson's disease: mechanisms and models.

Authors:  William Dauer; Serge Przedborski
Journal:  Neuron       Date:  2003-09-11       Impact factor: 17.173

Review 6.  Pink1, Parkin, DJ-1 and mitochondrial dysfunction in Parkinson's disease.

Authors:  Mark W Dodson; Ming Guo
Journal:  Curr Opin Neurobiol       Date:  2007-05-11       Impact factor: 6.627

7.  Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton.

Authors:  D D Sarbassov; Siraj M Ali; Do-Hyung Kim; David A Guertin; Robert R Latek; Hediye Erdjument-Bromage; Paul Tempst; David M Sabatini
Journal:  Curr Biol       Date:  2004-07-27       Impact factor: 10.834

8.  Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive.

Authors:  Estela Jacinto; Robbie Loewith; Anja Schmidt; Shuo Lin; Markus A Rüegg; Alan Hall; Michael N Hall
Journal:  Nat Cell Biol       Date:  2004-10-03       Impact factor: 28.824

9.  Phosphorylation of p38 MAPK induced by oxidative stress is linked to activation of both caspase-8- and -9-mediated apoptotic pathways in dopaminergic neurons.

Authors:  Won-Seok Choi; Dae-Seok Eom; Baek S Han; Won K Kim; Byung H Han; Eui-Ju Choi; Tae H Oh; George J Markelonis; Jin W Cho; Young J Oh
Journal:  J Biol Chem       Date:  2004-03-01       Impact factor: 5.157

Review 10.  Initiation of neuronal damage by complex I deficiency and oxidative stress in Parkinson's disease.

Authors:  Laszlo Tretter; Ildiko Sipos; Vera Adam-Vizi
Journal:  Neurochem Res       Date:  2004-03       Impact factor: 3.996

View more
  51 in total

1.  Maduramicin induces cardiac muscle cell death by the ROS-dependent PTEN/Akt-Erk1/2 signaling pathway.

Authors:  Xin Chen; Yue Li; Meng Feng; Xiaoyu Hu; Hai Zhang; Ruijie Zhang; Xiaoqing Dong; Chunxiao Liu; Zhao Zhang; Shanxiang Jiang; Shile Huang; Long Chen
Journal:  J Cell Physiol       Date:  2018-12-03       Impact factor: 6.384

2.  Synthesis, characterization and efficacy of mitochondrial targeted delivery of TPP-curcumin in rotenone-induced toxicity.

Authors:  Whidul Hasan; Rajesh Kumar Kori; Khilashwar Thakre; Rajesh Singh Yadav; Deepali Jat
Journal:  Daru       Date:  2019-07-01       Impact factor: 3.117

3.  Repurposing GLP-1 Receptor Agonists for Parkinson's Disease: Current Evidence and Future Opportunities.

Authors:  Daniella Balduino Victorino; Mariana Nejm; Marcia Guimarães-Marques; Fulvio Alexandre Scorza; Carla Alessandra Scorza
Journal:  Pharmaceut Med       Date:  2021-01-07

4.  Neurotoxin mechanisms and processes relevant to Parkinson's disease: an update.

Authors:  Juan Segura-Aguilar; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2015-01-29       Impact factor: 3.911

Review 5.  Metabolic Dysfunction in Parkinson's Disease: Bioenergetics, Redox Homeostasis and Central Carbon Metabolism.

Authors:  Annadurai Anandhan; Maria S Jacome; Shulei Lei; Pablo Hernandez-Franco; Aglaia Pappa; Mihalis I Panayiotidis; Robert Powers; Rodrigo Franco
Journal:  Brain Res Bull       Date:  2017-03-21       Impact factor: 4.077

6.  Glucose Metabolism and AMPK Signaling Regulate Dopaminergic Cell Death Induced by Gene (α-Synuclein)-Environment (Paraquat) Interactions.

Authors:  Annadurai Anandhan; Shulei Lei; Roman Levytskyy; Aglaia Pappa; Mihalis I Panayiotidis; Ronald L Cerny; Oleh Khalimonchuk; Robert Powers; Rodrigo Franco
Journal:  Mol Neurobiol       Date:  2016-06-20       Impact factor: 5.590

Review 7.  Targeting molecules to medicine with mTOR, autophagy and neurodegenerative disorders.

Authors:  Kenneth Maiese
Journal:  Br J Clin Pharmacol       Date:  2015-12-26       Impact factor: 4.335

8.  mTOR/AMPK signaling in the brain: Cell metabolism, proteostasis and survival.

Authors:  Carla Garza-Lombó; Annika Schroder; Elsa M Reyes-Reyes; Rodrigo Franco
Journal:  Curr Opin Toxicol       Date:  2018-05-17

9.  AMP-activated protein kinase activation in mediating phenylalanine-induced neurotoxicity in experimental models of phenylketonuria.

Authors:  Lihua Lu; Xiaoming Ben; Lingling Xiao; Min Peng; Yongjun Zhang
Journal:  J Inherit Metab Dis       Date:  2017-12-11       Impact factor: 4.982

Review 10.  Manganese and the Insulin-IGF Signaling Network in Huntington's Disease and Other Neurodegenerative Disorders.

Authors:  Miles R Bryan; Aaron B Bowman
Journal:  Adv Neurobiol       Date:  2017
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.